Power Law company profile

Intercept Pharmaceuticals

Biotech & Life Sciences · New York City, United States · Founded 2002 · IPO 2012 Thoroughbred

A biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases

Valuation

$456M

Market cap · 2026

Revenue

$361M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

2 investors on Intercept Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Genextra

Series B+ 1 investor entered at this stage

OrbiMed

Global footprint

Where Intercept Pharmaceuticals has talent and traffic

Workforce by country

12 countries with
team presence

🇺🇸 United States87.5%

🇬🇧 United Kingdom4.7%

🇪🇸 Spain2.4%

🇮🇹 Italy1.3%

🇦🇹 Austria0.4%

Top 5 of 12 shown

Web traffic by country

10K monthly visits
across markets

🇺🇸 United States70%

🇬🇧 United Kingdom13%

🇮🇳 India8%

🇨🇦 Canada7%

🇵🇰 Pakistan2%

Top 5 markets shown

Market sentiment

What the market is saying about Intercept Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Intercept Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intercept Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles